RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
86 hedge funds and large institutions have $235M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
26% less capital invested
Capital invested by funds: $317M → $235M (-$81.5M)
Holders
86
Holding in Top 10
3
Calls
$383K
Puts
$262K
Top Buyers
| 1 | +$6.67M | |
| 2 | +$5.13M | |
| 3 | +$2.56M | |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$767K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$513K |
Top Sellers
| 1 | -$7.32M | |
| 2 | -$1.39M | |
| 3 | -$1.14M | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.11M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.09M |